IRIDEX Corporation — FY2013 Form 10-K
Reporting period: Fiscal year ended December 28, 2013 (52 weeks). Although the request identifies 2013 Q4, this filing reports annual results, not standalone fourth-quarter results. IRIDEX is a medical-device company focused on ophthalmic laser consoles, delivery devices, consumables, and service. The aesthetics business was sold in February 2012 and is reported as discontinued operations.
Financial performance and position
| Metric | FY2013 | FY2012 |
|---|---|---|
| Revenue | $38.3 million | $33.9 million |
| Gross profit / margin | $18.6 million / 48.6% | $16.3 million / 48.3% |
| Operating income (continuing operations) | $2.6 million | $(0.9) million |
| Continuing-operations net income (loss) | $2.2 million | $(0.2) million |
| Net income, including discontinued operations | $2.2 million | $1.4 million |
| Basic / diluted EPS | $0.24 / $0.22 | $0.16 / $0.16 |
| Cash from continuing operating activities | $0.8 million | $(1.1) million |
| Cash and cash equivalents at year-end | $13.4 million | $11.9 million |
| Working capital | $24.6 million | $20.7 million |
| Debt | None | None |
FY2013 revenue comprised $19.3 million of laser-system sales, $18.7 million of recurring revenue, and $0.3 million of OEM revenue. International sales were $17.2 million, or 45.0% of revenue. The balance sheet reported $31.97 million of current assets and $7.36 million of current liabilities.
Changes versus prior periods
- Revenue increased 13.0% year over year, with growth in both system sales and recurring revenue. System sales rose to $19.3 million from $16.5 million; recurring revenue rose to $18.7 million from $17.1 million.
- Gross margin improved 0.3 percentage points to 48.6%, attributed to overhead efficiencies and cost reductions, partly offset by product mix.
- Operating expenses declined to $16.0 million from $17.2 million. R&D fell to $3.7 million from $4.4 million, while sales and marketing was $7.7 million versus $7.9 million.
- Operating cash flow returned to positive territory, but inventory and accounts receivable together used approximately $4.4 million of cash during FY2013.
- FY2012 net income included $1.6 million of after-tax income from discontinued operations, including the gain on the aesthetics-business sale; FY2013 had no discontinued-operations income.
Outlook, commentary, and risks
- Management aims to sustain profitability and pursue growth through wider adoption of MicroPulse technology, product innovation, and recurring consumables and service revenue. It anticipates increased R&D spending for new products and cost-reduction programs; no specific revenue or earnings guidance was provided.
- Management said cash and expected operating cash flows were sufficient for the next 12 months. The company had $13.4 million in cash, no debt, and $4.25 million in disclosed operating-lease and supplier commitments.
- Growth drivers cited include aging populations, diabetes, and demand for cost-effective ophthalmic care. Risks include competition from other device makers and pharmaceutical treatments, reimbursement uncertainty, reliance on international distributors, and dependence on sole- or limited-source suppliers.
- International sales expose the company to distributor, regulatory, political, collection, and currency-related risks. Sales are generally denominated in U.S. dollars, and the company did not hedge currency exposure.
- FY2013 included a $0.47 million insurance-carrier demutualization benefit in operating expenses and a $0.36 million expense from remeasuring acquisition earn-out liabilities. The company also recorded a $0.03 million tax provision; deferred tax assets of $9.97 million remained fully valuation-allowanced.
- Legal proceedings were described as ordinary-course matters not expected by management to have a material adverse effect. The filing also discusses product-liability, regulatory, clinical-development, manufacturing, and intellectual-property risks.
Investor verification priorities
- Review the audited financial statements and confirm the distinction between annual FY2013 results and standalone Q4 results.
- Assess whether revenue growth—particularly recurring revenue and MicroPulse system sales—can continue as OEM sales from Bausch & Lomb are expected to end.
- Monitor cash conversion, especially the increase in inventory to $10.6 million and receivables to $7.3 million, as well as supplier commitments and earn-out liabilities.
- Evaluate the assumptions behind management’s 12-month liquidity assessment and anticipated increase in R&D spending.
- Track realization of tax attributes, including the full deferred-tax valuation allowance and potential limitations on net operating losses and credits.